MetLife Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Earnings: Approximately $1.6 billion, or $2.43 per share, up 15% year-over-year; adjusted EPS increased 20%.

Adjusted Return on Equity (ROE): 17%, at the top end of the 15%-17% target range for the second consecutive quarter.

Adjusted Premiums, Fees, and Other Revenues: Increased 5% year-over-year, excluding pension risk transfers.

Sales Growth: Rose 7%, driven by strong performance in international markets.

Variable Investment Income: Totaled $231 million pretax, higher than the prior year.

Direct Expense Ratio: 12.1%, in line with full-year targets despite the integration of PineBridge Investments.

2Strategic Updates and Business Highlights

MetLife's New Frontier strategy is yielding positive results, focusing on two earnings engines: capital-light (Group Benefits, Latin America, EMEA, Asset Management) and capital-driven (Retirement and Income Solutions).

Group Benefits: Adjusted earnings of $503 million, up 25% year-over-year, with a favorable Group Life mortality ratio of 79%.

Retirement and Income Solutions (RIS): Adjusted earnings of $377 million, up 2%, with a 19% increase in adjusted PFOs excluding pension risk transfers.

Asia: Adjusted earnings of $420 million, up 21% year-over-year, with sales growth of 17% on a constant currency basis.

Latin America: Achieved record adjusted earnings of $268 million, a 15% increase, with strong sales and persistency.

MetLife Investment Management (MIM): Adjusted earnings of $57 million, up 6%, with total assets under management reaching approximately $748 billion.

3Forward Guidance and Outlook

MetLife remains confident in its capital generation and long-term outlook, announcing a new $3 billion share repurchase authorization.

The company expects to maintain disciplined expense management and continue pursuing organic growth opportunities while being open to strategic M&A in asset management and group benefits.

RIS anticipates growth in retained balance of 3%-5% for the full year, with a stronger pipeline for the second half of 2026.

4Bad News, Challenges, or Points of Concern

Normalization of Mortality Trends: Favorable mortality trends in Group Life may not sustain; normalization expected in the second half of the year.

Private Equity Returns: Lower returns in private equity impacted variable investment income; future performance remains uncertain.

Pension Risk Transfer (PRT) Market: The first half of 2026 has seen lighter activity compared to a record 2025, though a stronger pipeline is anticipated for Q3 and Q4.

Expense Management: While the direct expense ratio is on target, the integration of PineBridge Investments has a structurally higher expense profile.

5Notable Q&A Insights

M&A Strategy: MetLife remains disciplined in its M&A approach, focusing on asset management and group benefits while being opportunistic in other areas.

Group Life Pricing: Future pricing adjustments may be necessary if favorable mortality trends continue; however, any changes would unfold gradually due to the business's renewal cycle.

Japan Market Dynamics: Despite market volatility, MetLife's strong distribution and product innovation are driving sales growth in Japan and other Asian markets.

Private Equity Positioning: The company is likely to see a modest decline in private equity allocation over time, with distributions expected to outpace contributions. Overall, MetLife's Q2 2026 results reflect strong performance across its business segments, driven by effective execution of its strategic initiatives, although there are concerns regarding the sustainability of favorable mortality trends and private equity returns.